Kymera Therapeutics (NASDAQ:KYMR) Stock Price Down 3.7%

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) traded down 3.7% during mid-day trading on Wednesday . The stock traded as low as $44.85 and last traded at $44.85. 42,861 shares were traded during trading, a decline of 93% from the average session volume of 622,012 shares. The stock had previously closed at $46.57.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on KYMR. Wolfe Research upgraded Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price objective for the company in a report on Monday, August 26th. B. Riley increased their price objective on Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 9th. Oppenheimer boosted their target price on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Friday, September 27th. HC Wainwright reaffirmed a “buy” rating and set a $46.00 price target on shares of Kymera Therapeutics in a research report on Monday, June 17th. Finally, Morgan Stanley boosted their price objective on shares of Kymera Therapeutics from $34.00 to $45.00 and gave the company an “equal weight” rating in a report on Wednesday, August 14th. Four analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $49.00.

Kymera Therapeutics Price Performance

The company has a market capitalization of $2.76 billion, a price-to-earnings ratio of -18.01 and a beta of 2.22. The firm’s fifty day moving average price is $45.95 and its 200-day moving average price is $39.42.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Wednesday, August 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.10. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. The business had revenue of $25.60 million during the quarter, compared to analysts’ expectations of $12.55 million. During the same quarter in the prior year, the firm earned ($0.67) EPS. The business’s revenue for the quarter was up 55.2% compared to the same quarter last year. On average, research analysts predict that Kymera Therapeutics, Inc. will post -2.87 earnings per share for the current year.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bruce Booth sold 453,960 shares of the business’s stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $38.21, for a total transaction of $17,345,811.60. Following the sale, the director now directly owns 723,246 shares of the company’s stock, valued at approximately $27,635,229.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Bruce Booth sold 453,960 shares of the firm’s stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $38.21, for a total transaction of $17,345,811.60. Following the completion of the transaction, the director now directly owns 723,246 shares of the company’s stock, valued at approximately $27,635,229.66. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Pamela Esposito sold 13,500 shares of Kymera Therapeutics stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The disclosure for this sale can be found here. Insiders sold a total of 495,605 shares of company stock worth $19,303,364 in the last quarter. 15.82% of the stock is owned by insiders.

Institutional Trading of Kymera Therapeutics

Several institutional investors have recently added to or reduced their stakes in KYMR. Comerica Bank lifted its position in shares of Kymera Therapeutics by 13.7% in the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after purchasing an additional 400 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in Kymera Therapeutics by 7.8% in the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock valued at $164,000 after buying an additional 295 shares during the period. Public Employees Retirement Association of Colorado bought a new stake in Kymera Therapeutics during the second quarter valued at $139,000. Virtu Financial LLC acquired a new stake in Kymera Therapeutics during the 1st quarter worth about $207,000. Finally, Quest Partners LLC grew its holdings in Kymera Therapeutics by 1,402.0% during the 2nd quarter. Quest Partners LLC now owns 5,212 shares of the company’s stock worth $156,000 after acquiring an additional 4,865 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.